SubjectWell Launches Patient Registry of 10k+ Patients for COVID-19 Clinical Trials
/What You Should Know:
– SubjectWell launches a patient registry list of 10,000 individuals in the US interested in participating in COVID-19 clinical trials and research.
– The new COVID-19 patient registry will accelerate the patient recruitment process for COVID-19 research, giving researchers access to interested individuals who could randomize for various types of trials, whether they are healthy volunteers with no previous exposure to COVID-19, currently sick with the virus, or who have recovered.
As the pharmaceutical industry mobilizes at unprecedented speed to develop a COVID-19 vaccine, SubjectWell, the world’s largest marketplace for clinical trials, announced today it has developed a growing patient registry of individuals in the US interested in participating in clinical trials for a COVID-19 vaccine as these trials become more widely available. In just three weeks, 10,000 people from SubjectWell’s expansive patient network have already opted into the list, with approximately 70,000 individuals expected to register by the end of May.
Why It Matters
With SubjectWell’s COVID-19 patient registry, researchers will have access to interested individuals who could randomize for various types of trials, whether they are healthy volunteers with no previous exposure to COVID-19, currently sick with the virus, or who have recovered. Patient data includes general demographic information, existing medical conditions, past virus diagnoses, past exposure to the virus and results of positive antigen tests. By sidestepping the lengthy process of identifying participants for a clinical trial, the list will dramatically accelerate last patient in (LPI), which could ultimately bring a safe, approved vaccine to the general public faster.